Contact

What are you looking for?

Lab Services News for Bio Pharmaceuticals

Welcome to Lab Services News for Bio/Pharmaceuticals. We explore the latest in bio/pharma testing requirements and product characterization, as well as providing details of our technical webinars and laboratory events.
Publication Date
Publication Topic
8 results found

SGS Joins Forces with Agilex Biolabs

SGS has formed a strategic partnership with Agilex Biolabs, Australia’s largest and most technologically advanced regulated bioanalytical laboratory.
Read more
SGS Selected to Establish On-site Lab for Liontown Resources

SGS Selected to Establish On-site Lab for Liontown Resources

This new laboratory will give Liontown Resources direct access to streamlined sample preparation and analytical services on the mine site.
Read more
Science Technology Concept

New Equipment, Expertise and Capacity at Two North American SGS Sites Accelerates Nitrosamine Testing for Customers

We are delighted to announce the expansion of our nitrosamine testing capabilities in two key laboratories, doubling our capacity for nitrosamine testing in North America.
Read more
Young Female Scientist Working in the CDC Laboratory

Our Biosafety Center of Excellence Receives Prestigious Award

We’ve been recognized at Scotland’s Life Sciences Annual Awards 2023.
Read more
Qingdao Lab

New Chemical Testing Lab Opens in Qingdao

A new SGS lab has opened in Qingdao, increasing the company’s chemical testing capabilities in China._x00D_
Read more
Testing Samples in SGS Glasgow Laboratory

Expansion of Glasgow Facility Completed

We have expanded the capacity of our Glasgow testing facility, in a major boost to the development of cell therapies, gene therapies, viral vaccines and other biological medicines.
Read more

Franck Picard, PhD, Joins SGS’s Life Sciences Business

Franck Picard PhD joins SGS as Business Manager of Life Sciences in France and Global Head of Bioanalysis.
Read more

Nitrosamine Detection: Meet EMA and FDA Regulations

By April 2020, all marketing authorization holders of medicines containing chemically synthesized APIs must have conducted a risk assessment to evaluate the possibility of nitrosamines being present.
Read more